UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
UK Retail Sales Rise as World Cup and Heatwave Boost Food, Pubs and Clothing 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Should I take zinc or eat oysters to ward off colds, boost my immune system or improve fertility? 
US Yen Intervention Unlikely to Deliver Lasting Recovery, Yardeni Says 
England Drought Expands to 71% as Heatwave Deepens Water Crisis 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency 
Gold Prices Rise as Fed Rate Hike Bets Ease 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
US Stock Futures Flat as Iran Strait of Hormuz Demands Fuel Oil Concerns 
Tokyo Medical and Dental University and the National Center of Neurology and Psychiatry are planning to develop tailored drugs for patients with genetic disorders to find treatment for extremely rare diseases.
The two Japanese medical institutions will search for rare diseases that have the potential to be treated by nucleic acid drugs from a database of around 2,250 patients.
Nucleic acid drugs are an emerging class of therapeutics,
The development will be carried out based on technology that targets the expression of disease-causing proteins in the mutant gene.
Due to the price and challenges with financial viability, pharmaceutical companies are hesitant to develop medications for exceedingly rare disorders.
According to Takanori Yokota, a professor of neurology and neurological science at Tokyo Medical and Dental University, they hope to make effective patient-tailored nucleic acid drugs and find as many people who can be treated.
The Initiative on Rare and Undiagnosed Diseases, a study that examines the DNA of people whose diseases cannot be detected or for which there is no known cure, will be used to pick participants from among the patients registered in it.
The project catalogs approximately 1,700 linked gene sequences and covers a wide spectrum of illnesses, such as neurological, cardiac, and metabolic problems.
In Japan, only one or two family lines are affected by about 70% of the diseases, and many do not have any reliable treatments.
In addition to the causative gene, factors such as age, the severity of symptoms, and the speed at which the disease is progressing will be taken into account when choosing candidate patients.
